Single-institution phase II trial of oxaliplatin, 5-fluorouracil, leucovorin [folinic acid] and bevacizumab (FOLFOX-B) for initially unresectable colorectal liver metastases: downstaging followed by hepatic resection.

Trial Profile

Single-institution phase II trial of oxaliplatin, 5-fluorouracil, leucovorin [folinic acid] and bevacizumab (FOLFOX-B) for initially unresectable colorectal liver metastases: downstaging followed by hepatic resection.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2012 Actual end date added as reported by ClinicalTrials.gov record.
    • 31 Jul 2012 Company changed from Sanofi-Synthelabo to Sanofi as reported by ClinicalTrials.gov record.
    • 14 Aug 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top